Blood Cancer Drugs Market Report 2026

Blood Cancer Drugs Market Overview

• Blood Cancer Drugs market size has reached to $79.6 billion in 2025 • Expected to grow to $111.86 billion in 2030 at a compound annual growth rate (CAGR) of 7.2% • Growth Driver: Rising Incidence Of Blood Cancer Cases Driving Market Growth Due To Increased Adoption Of Personalized And Targeted Therapies • Market Trend: Bristol Myers Squibb Secures FDA Approval for First CAR T-Cell Therapy Targeting Relapsed CLL and SLL Patients • North America was the largest region in 2025 and Middle East is the fastest growing region.

What Is Covered Under Blood Cancer Drugs Market?

Blood Cancer Drugs Blood cancer drugs refer to the drugs or medications that are used to treat blood cancer drugs by using the body's immune system to fight blood cancer by slowing down the growth of cancer cells. Chemotherapy, biological therapy, targeted therapy, radiation therapy, and stem cell transplant are a few of the frequently used blood cancer treatments. The main types of blood cancer drugs are leukemia, and lymphoma. Leukemia is a blood-forming tissue cancer that affects the bone marrow and lymphatic tract. The different types of drugs include rituaxan/Mabthera (rituximab), Gleevec/Glivec (imatinib), Revlimid (lenalidomide), Velcade (bortezomib), Tasigna (nilotinib), pomalyst (pomalidomide), Fidanza (azacitidine), kyphosis (carfilzomib), advertise (brentuximabvedotin), others and involve various treatment approaches such as key findings, chemotherapeutic, mabs/targeted therapies, immunotherapeutic.

What Is The Blood Cancer Drugs Market Growth Forecast?

The blood cancer drugs market size is expected to see strong growth in the next few years. It will grow to $111.86 billion in 2030 at a compound annual growth rate (CAGR) of 7.2%. The growth in the forecast period can be attributed to growth in precision oncology, increasing adoption of stem cell therapies, innovation in biologics, rising healthcare expenditure, expansion of cancer screening programs. Major trends in the forecast period include rising adoption of targeted blood cancer therapies, growing use of immunotherapy in hematologic malignancies, expansion of combination treatment approaches, increasing focus on personalized cancer treatment, improved survival outcomes in blood cancer patients.

Global Blood Cancer Drugs Market Segmentation

1) By Blood Cancer Type: Leukemia, Lymphoma 2) By Drugs: Rituxan Or Mabthera (Rituximab), Gleevec Or Glivec (Imatinib), Revlimid (Lenalidomide), Velcade (Bortezomib), Tasigna (Nilotinib), Pomalyst (Pomalidomide), Vidaza (Azacitidine), Kyprolis (Carfilzomib), Adcetris (Brentuximab Vedotin), Other Drugs 3) By Treatment Approaches: Chemotherapeutic, MAbs/Targeted Therapies, Immunotherapeutic Subsegments: 1) By Leukemia: Acute Lymphoblastic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL), Acute Myeloid Leukemia (AML), Chronic Myeloid Leukemia (CML), Other Types of Leukemia 2) By Lymphoma: Hodgkin Lymphoma, Non-Hodgkin Lymphoma (NHL), Burkitt Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma, Other Types of Lymphoma

What Is The Driver Of The Blood Cancer Drugs Market?

The increasing incidence of blood cancer cases globally is expected to drive the growth of the blood cancer drug market going forward. Blood cancer refers to a group of malignant conditions, including leukemia, lymphoma, and myeloma, that affect the blood and bone marrow and require long-term, specialized treatment involving chemotherapy, immunotherapy, targeted drugs, and stem cell transplantation. This rise in disease prevalence is due to factors such as aging populations, genetic mutations, environmental exposures, and lifestyle-related risks. The growing number of blood cancer cases is contributing to increased demand for innovative blood cancer drugs that offer improved survival rates, fewer side effects, enhanced patient quality of life, and personalized treatment strategies. For instance, in October 2025, according to Blood Cancer United, a US-based blood cancer information and advocacy organization, an estimated 66,890 people were expected to be diagnosed with leukemia, with about 475,323 individuals living with or in remission from the disease in the United States and approximately 23,540 deaths expected to be attributed to leukemia in 2025. Therefore, the increasing incidence of blood cancer cases globally is driving the growth of the blood cancer drug industry.

Key Players In The Global Blood Cancer Drugs Market

Major companies operating in the blood cancer drugs market are Amgen Inc., AstraZeneca PLC, Bayer AG, Eli Lilly and Company Inc., Johnson & Johnson, Novartis AG, Pfizer Inc., AbbVie Inc., Takeda Pharmaceutical Company Limited, F. Hoffmann-La Roche Ltd., Bristol-Myers Squibb Company, Astellas Pharma Inc., Merck & Co. Inc., Gilead Sciences Inc., Sanofi S.A., Eisai Co. Ltd., Jazz Pharmaceuticals plc, Kyowa Kirin Co. Ltd., Menarini Group, Millennium Pharmaceuticals Inc., Mundipharma International Limited, Mylan N.V., Ono Pharmaceutical Co. Ltd., Otsuka Pharmaceutical Co. Ltd., Pharmacyclics LLC, Seattle Genetics Inc., Servier Laboratories, Shire plc, Spectrum Pharmaceuticals Inc., Taiho Pharmaceutical Co. Ltd., Teva Pharmaceutical Industries Ltd., Tolero Pharmaceuticals Inc., UCB S.A.

Global Blood Cancer Drugs Market Trends and Insights

Major companies operating in the blood cancer drugs market are focusing on developing new drugs and pushing for FDA approval to gain a competitive edge in the market. FDA approval for drugs refers to the formal authorization granted by the United States Food and Drug Administration (FDA) for a pharmaceutical product to be legally marketed and sold in the United States. For instance, in March 2024, Bristol Myers Squibb, a US-based pharmaceutical industry company, received FDA approval for its first and only CAR T-cell therapy for adults with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). This accelerated approval allows its use in patients who have received at least two prior treatments, including a Bruton tyrosine kinase inhibitor and a B-cell lymphoma 2 inhibitor. Based on the TRANSCEND CLL 004 trial, Breyanzi demonstrated a 20% complete response rate and a median duration of response of 35.3 months among responders.

What Are Latest Mergers And Acquisitions In The Blood Cancer Drugs Market?

In May 2025, Helix Biopharma, a Canada-based biopharmaceutical company, acquired the Laevoroc Immunology AG and Laevoroc Chemotherapy AG, for an undisclosed amount. Through this acquisition, Helix Biopharma aims to strengthen its blood cancer drug portfolio by integrating these novel oncology candidates into its pipeline, enabling the development of innovative therapies for hematologic malignancies. Laevoroc Group is a Canada-based biotechnology company specializing in early-stage oncology drug candidates with a strong track record in preclinical research and development.

Regional Insights

North America was the largest region in the blood cancer drugs market in 2025. Middle East is expected to be the fastest-growing region in the blood cancer drugs market during the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Blood Cancer Drugs Market?

The blood cancer drugs market consists of sales Altretamine, Bendamustine, Bendamustine, and Carboplatin. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Blood Cancer Drugs Market Report 2026?

The blood cancer drugs market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the blood cancer drugs industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.